$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000145368724000082 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$33.45M	$5.840M
YoY Change	537.17%	-1.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.027M	$9.450M
YoY Change	15.1%	65.94%
% of Gross Profit
Research & Development	$12.66M	$9.738M
YoY Change	-28.8%	-47.71%
% of Gross Profit
Depreciation & Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$19.69M	$19.19M
YoY Change	-17.58%	-21.1%
Operating Profit	$13.76M	-$13.35M
YoY Change	-173.81%	-27.38%
Interest Expense	$1.195M	$0.00
YoY Change	58.91%	-100.0%
% of Operating Profit	8.69%
Other Income/Expense, Net	$292.0K	$508.0K
YoY Change	19.18%	99.22%
Pretax Income	$13.84M	-$56.82M
YoY Change	-221.51%	162.31%
Income Tax
% Of Pretax Income
Net Earnings	$13.84M	-$56.82M
YoY Change	-221.51%	162.31%
Net Earnings / Revenue	41.37%	-973.01%
Basic Earnings Per Share	$0.58	-$10.50
Diluted Earnings Per Share	$0.54	-$10.50
COMMON SHARES
Basic Shares Outstanding	17.80M shares	161.9M shares
Diluted Shares Outstanding	17.79M shares	5.414M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$87.23M	$103.4M
YoY Change	-22.14%	-17.87%
Cash & Equivalents	$87.23M	$103.4M
Short-Term Investments
Other Short-Term Assets	$2.044M	$3.315M
YoY Change	-52.0%	-12.42%
Inventory
Prepaid Expenses
Receivables	$32.04M	$2.006M
Other Receivables	$3.472M	$2.370M
Total Short-Term Assets	$124.8M	$111.1M
YoY Change	1.68%	-19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.672M	$2.402M
YoY Change	157.31%	-13.13%
Goodwill	$48.16M	$48.16M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Other Assets	$1.669M	$1.377M
YoY Change	18.12%	3.15%
Total Long-Term Assets	$223.0M	$214.1M
YoY Change	1228.62%	1137.49%
TOTAL ASSETS
Total Short-Term Assets	$124.8M	$111.1M
Total Long-Term Assets	$223.0M	$214.1M
Total Assets	$347.7M	$325.2M
YoY Change	149.26%	108.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.862M	$2.517M
YoY Change	971.91%	136.78%
Accrued Expenses	$10.62M	$8.927M
YoY Change	-17.73%	-4.49%
Deferred Revenue	$0.00	$412.0K
YoY Change	-100.0%	-90.26%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.12M	$36.65M
YoY Change	-11.07%	38.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$407.2M	$389.5M
YoY Change	1217.72%	915.51%
Total Long-Term Liabilities	$407.2M	$389.5M
YoY Change	811.21%	613.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.12M	$36.65M
Total Long-Term Liabilities	$407.2M	$389.5M
Total Liabilities	$449.2M	$442.0M
YoY Change	506.55%	444.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$657.6M	-$671.5M
YoY Change	53.65%	61.19%
Common Stock	$2.000K	$1.000K
YoY Change	-86.67%	-93.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$101.5M	-$116.8M
YoY Change
Total Liabilities & Shareholders Equity	$347.7M	$325.2M
YoY Change	149.26%	108.88%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$13.84M	-$56.82M
YoY Change	-221.51%	162.31%
Depreciation, Depletion And Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$14.45M	-$15.92M
YoY Change	45.99%	81.6%
INVESTING ACTIVITIES
Capital Expenditures	$1.587M	$602.0K
YoY Change	13125.0%	363.08%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$1.587M	-$602.0K
YoY Change	13125.0%	-102.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	120.0K	$43.03M
YoY Change	-104.64%	28779.87%
NET CHANGE
Cash From Operating Activities	-14.45M	-$15.92M
Cash From Investing Activities	-1.587M	-$602.0K
Cash From Financing Activities	120.0K	$43.03M
Net Change In Cash	-15.91M	$26.51M
YoY Change	27.38%	36.02%
FREE CASH FLOW
Cash From Operating Activities	-$14.45M	-$15.92M
Capital Expenditures	$1.587M	$602.0K
Free Cash Flow	-$16.03M	-$16.52M
YoY Change	61.84%	85.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Net Derivative Asset Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#GainLossOnDerivativeInstrumentsNetPretax
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	435120.513	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	435120.513	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5397597	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5397597	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9738000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18624000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9450000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5695000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	19188000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	24319000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13348000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18381000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1164000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1331000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	19000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	808000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1042000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4079000	usd
CY2024Q1	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	39300000	usd
CY2023Q1	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-6890000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	508000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	255000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-56824000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56829000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21674000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.50
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.50
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.24
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.24
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5414020	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5414020	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5111518	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5111518	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	435120.513	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	296851000	usd
CY2023Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	3703000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-440184000	usd
CY2024Q1	rnac	Temporary Equity Stock Issued During Period Shares TemporaryEquityStockIssuedDuringPeriodShares	99140.326	shares
CY2024Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	75197000	usd
CY2024Q1	rnac	Temporary Equity Transfer Of Preferred Stock To Permanent Equity Shares TemporaryEquityTransferOfPreferredStockToPermanentEquityShares	534260.839	shares
CY2024Q1	rnac	Temporary Equity Transfer Of Preferred Stock To Permanent Equity TemporaryEquityTransferOfPreferredStockToPermanentEquity	372048000	usd
CY2024Q1	rnac	Temporary Equity Options Transfer Of Preferred Stock To Permanent Equity TemporaryEquityOptionsTransferOfPreferredStockToPermanentEquity	3703000	usd
CY2024Q1	rnac	Transfer Of Temporary Equity To Permanent Equity TransferOfTemporaryEquityToPermanentEquity	375751000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	154000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2877000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1431000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-56824000	usd
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2024Q1	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	0	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-116800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	93828000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	149000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2276000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	74579000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-56824000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21663000	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	183000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	206000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	79000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	512000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	416000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1431000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2276000	usd
CY2024Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	398000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1042000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4079000	usd
CY2024Q1	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	39300000	usd
CY2023Q1	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-6890000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3864000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	243000	usd
CY2024Q1	rnac	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	-611000	usd
CY2023Q1	rnac	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	-1319000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1652000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-633000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	747000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5437000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9158000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6426000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5359000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15917000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8765000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	28254000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	602000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	130000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-602000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28124000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2877000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	40000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	154000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	149000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43031000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	149000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26507000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19487000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78288000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108038000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104795000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127525000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	625000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	48000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q1	rnac	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	104800000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1400000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-671500000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-56824000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-56824000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21663000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21663000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5414020	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5414020	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5111518	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5111518	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.50
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.50
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.24
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.24
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21065841	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1814430	shares
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103418000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125925000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	289000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1377000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104795000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127525000	usd
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	148710.488	shares
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	28307000	usd
CY2024Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	35197000	usd
CY2024Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-6890000	usd
CY2024Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	0	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8232000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7841000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5830000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5728000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2402000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2113000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1701000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4390000	usd
CY2024Q1	rnac	Accrued Patent Fees Current AccruedPatentFeesCurrent	1177000	usd
CY2023Q4	rnac	Accrued Patent Fees Current AccruedPatentFeesCurrent	472000	usd
CY2024Q1	rnac	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2614000	usd
CY2023Q4	rnac	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4896000	usd
CY2024Q1	rnac	Accrued Audit Fees Current AccruedAuditFeesCurrent	3055000	usd
CY2023Q4	rnac	Accrued Audit Fees Current AccruedAuditFeesCurrent	4331000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	380000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	644000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8927000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14733000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	775000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	696000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	397000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	142000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	510000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	255000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	665000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	586000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2316000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3164000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3248000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3017000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	946000	usd
CY2024Q1	rnac	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	12691000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2234000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10457000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	761000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	653000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.099
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	548375	shares
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	148710.488	shares
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	49570.162	shares
CY2024Q1	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	49570.163	shares
CY2024Q1	rnac	Number Of Business Days NumberOfBusinessDays	8	business_day
CY2023Q4	rnac	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	5849000	usd
CY2024Q1	rnac	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	0	usd
CY2024Q1	rnac	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	-5437000	usd
CY2024Q1	rnac	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	412000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5849000	usd
CY2024Q1	rnac	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	0	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-5437000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1040813	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	45.98
CY2024Q1	rnac	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	65681	shares
CY2024Q1	rnac	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercises ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises	43.80
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	975132	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	46.12
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	21268716	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1431000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2276000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.79
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26.87
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	400000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	412000	usd
CY2024Q1	rnac	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P2Y
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2024Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.79
CY2023	us-gaap	Restructuring Charges RestructuringCharges	6400000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2500000	usd
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	300000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3300000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	3896000	usd
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	292000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3320000	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	868000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
exhibit321_3312024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
firstamendmenttoleaseagree.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
0001453687-24-000082-index-headers.html	Edgar Link	pending
0001453687-24-000082-index.html	Edgar Link	pending
0001453687-24-000082.txt	Edgar Link	pending
0001453687-24-000082-xbrl.zip	Edgar Link	pending
exhibit311_3312024.htm	Edgar Link	pending
exhibit312_3312024.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnac-20240331.htm	Edgar Link	pending
rnac-20240331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rnac-20240331_cal.xml	Edgar Link	unprocessable
rnac-20240331_def.xml	Edgar Link	unprocessable
rnac-20240331_lab.xml	Edgar Link	unprocessable
rnac-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
rnac-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2024 Q2 Form 10-Q Financial Statement

#000145368724000082 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2024 Q2 Form 10-Q Financial Statement

#000145368724000082 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac